相关实验视频

Updated: Sep 10, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

通过稳定MGMT在质母细胞瘤中,USP7促进了temozolomide耐药性

Jiabing Li¹, Xiaorong Feng¹, Zhaohui Liu¹

¹The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, Hunan, 410081, China.

Cell death & disease

|August 20, 2025

概括

乌比基特异性蛋白酶7 (USP7) 稳定了O6-甲基氨酸-DNA-甲基转移酶 (MGMT),在质母细胞瘤中产生了对temozolomide (TMZ) 的耐药性. 抑制USP7降低了MGMT,提高了TMZ的疗效,改善了患者的存活率.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

质母细胞瘤 (GBM) 是一种具有不良预后的致命脑瘤.
泰莫佐洛米德 (TMZ) 耐药性,通常是由于O6-甲基氨酸-DNA-甲基转移酶 (MGMT),限制了治疗疗效.

研究的目的:

识别MGMT稳定性和质母细胞瘤 (GBM) 耐泰莫索洛米德 (TMZ) 的新型调节剂.
研究乌比基特异蛋白酶7 (USP7) 在DNA修复途径和质母细胞瘤治疗中的作用.

主要方法:

使用生物化学测试研究了USP7与MGMT的相互作用.
评估了USP7抑制/淘汰对MGMT水平和DNA修复蛋白 (XPC,ALKBH2,ALKBH3) 的影响.
通过组织微阵列分析了患者组织中的USP7和MGMT联合表达.

主要成果:

USP7直接与MGMT结合,防止其蛋白质体降解并稳定其水平.
USP7抑制/敲除减少了MGMT和其他DNA修复蛋白,损害了DNA修复能力.
在GBM中USP7和MGMT的共同过度表达与患者的生存率差相关.

结论:

USP7是MGMT稳定的核调节者,也是DNA化修复通路的关键整合者.
准USP7使质母细胞瘤细胞对TMZ敏感,提供克服化疗抵抗的策略.
抑制USP7可以提高TMZ的疗效,从而降低剂量并改善患者的治疗结果.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...